عنوان
پدید آورنده
موضوع
رده
RC280.L9
RC280
.
L9
کتابخانه
محل استقرار
INTERNATIONAL STANDARD BOOK NUMBER
(Number (ISBN
331978238X
(Number (ISBN
9783319782386
Erroneous ISBN
3319782371
Erroneous ISBN
9783319782379
TITLE AND STATEMENT OF RESPONSIBILITY
Title Proper
Resistance to ibritumomab in lymphoma /
General Material Designation
[Book]
First Statement of Responsibility
Makoto Hosono, Jean-François Chatal, editors.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Cham :
Name of Publisher, Distributor, etc.
Springer,
Date of Publication, Distribution, etc.
[2018]
Date of Publication, Distribution, etc.
©2018
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
1 online resource :
Other Physical Details
illustrations
SERIES
Series Title
Resistance to targeted anti-cancer therapeutics ;
Volume Designation
volume 18
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and index.
CONTENTS NOTE
Text of Note
Intro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Preface; Biography of Series Editor; Acknowledgments; Contents; Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma; 1 Introduction; 2 Characteristics of Zevalin; 3 Treatment Schedule and Dosage of Zevalin; 4 Patient Eligibility; 5 Zevalin in Relapse or Refractory Patients; 6 Zevalin in Frontline Therapy; 7 Toxicities and Safety Profile; 8 Factor Associated with Effects of Zevalin; 9 Future Aspects; References; Biology and Pathology of B-Cell Lymphoma; 1 Introduction; 2 Cellular Origin of B-Cell Lymphomas.
Text of Note
3 Features of Ibritumomab4 A Model of Theranostic Approach; 5 Enhancing Efficacy of Ibritumomab Tiuxetan; 6 Conclusion; References; Radiological Evaluation of Response and Resistance of Ibritumomab; 1 Introduction; 2 Evaluation of FDG-PET/CT for Monitoring the Response to RIT; 2.1 FDG-PET/CT Imaging; 3 Summary of the Results; 4 Discussion; 5 Conclusions; References; Characteristics of Ibritumomab as Radionuclide Therapy Agent; 1 Introduction; 2 CD 20: B-Cell Antigen; 3 mAb Targeting CD20; 4 Ibritumomab Tiuxetan Coupled with Radioisotopes; 4.1 Ibritumomab; 4.2 Tiuxetan; 4.3 Radionuclides.
Text of Note
5 Conclusions and PerspectivesReferences; Radiation Dosimetry in Ibritumomab Therapy; 1 Introduction; 2 Activity Escalation Trial and Dose Escalation Trial; 3 Dosimetry for Molecular Radiotherapy; 3.1 Quantification of Pharmacokinetics; 3.2 Kinetic Model; 3.3 Prediction of Pharmacokinetics During Therapy; 3.4 Absorbed Dose Calculations; 3.5 Treatment Planning; 3.6 Treatment and Quality Control Measurements; 3.7 Conclusion; 4 Dosimetry for Ibritumomab Tiuxetan; 5 Treatment Planning for [90Y]Ibritumomab Tiuxetan; 6 Conclusion and Outlook; References.
Text of Note
5 Yttrium-90 (90Y)6 Indium-111 (111In); 7 Preclinical Investigation of 90Y-/111In-Ibritumomab Tiuxetan; 7.1 In Vitro Studies; 7.2 Ex Vivo/In Vivo Studies; 8 Imaging and Therapy Protocol; 8.1 Preparation of 90Y-Ibritumomab Tiuxetan; 8.2 Schedule of 90Y-Ibritumomab Tiuxetan Therapy; 9 Perspectives and Conclusion; References; Resistance and Heterogeneity of Intratumoral Antibody Distribution; 1 Introduction; 2 SPECT/CT and PET/CT System; 3 Statistical Approach Taken to Characterize Lesion's Uptake; 4 Resistance and Heterogeneity of Intratumoral Antibody Distribution.
0
8
8
8
SUMMARY OR ABSTRACT
Text of Note
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
ACQUISITION INFORMATION NOTE
Source for Acquisition/Subscription Address
Springer Nature
Stock Number
com.springer.onix.9783319782386
OTHER EDITION IN ANOTHER MEDIUM
Title
Resistance to ibritumomab in lymphoma.
International Standard Book Number
9783319782379
TOPICAL NAME USED AS SUBJECT
Drug resistance in cancer cells.
Lymphomas-- Treatment.
Biomedicine.
Cancer Research.
Drug resistance in cancer cells.
HEALTH & FITNESS-- Diseases-- General.
Lymphomas-- Treatment.
MEDICAL-- Clinical Medicine.
MEDICAL-- Diseases.
MEDICAL-- Evidence-Based Medicine.
MEDICAL-- Internal Medicine.
Oncology.
(SUBJECT CATEGORY (Provisional
HEA-- 039000
MED-- 014000
MED-- 022000
MED-- 045000
MED-- 112000
MJCL
DEWEY DECIMAL CLASSIFICATION
Number
616
.
99/446
Edition
23
LIBRARY OF CONGRESS CLASSIFICATION
Class number
RC280
.
L9
PERSONAL NAME - ALTERNATIVE RESPONSIBILITY
Chatal, Jean-François,1939-
Hosono, Makoto
ORIGINATING SOURCE
Date of Transaction
20200823113118.0
Cataloguing Rules (Descriptive Conventions))
pn
ELECTRONIC LOCATION AND ACCESS
Electronic name
مطالعه متن کتاب [Book]
Y
